5 results on '"D’Ambrosio, Michele"'
Search Results
2. Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.
- Author
-
Fadini, Gian Paolo, Frison, Vera, Rigato, Mauro, Morieri, Mario Luca, Simioni, Natalino, Tadiotto, Federica, D'Ambrosio, Michele, Paccagnella, Agostino, Lapolla, Annunziata, and Avogaro, Angelo
- Subjects
TYPE 2 diabetes ,GLUCAGON-like peptide-1 agonists ,CARDIOVASCULAR diseases risk factors ,SCIENTIFIC observation ,BLOOD cholesterol ,INSULIN aspart ,SODIUM-glucose cotransporters - Abstract
Aims: Several GLP-1 receptor agonists (GLP-1RA) have become available for the treatment of type 2 diabetes (T2D), and evidence on their beneficial effects has evolved. We evaluated how the clinical phenotype of patients initiating GLP-1RA changed from 2010 to 2018. Methods: This was a retrospective study conducted at six diabetes outpatient clinics in Northeast Italy. We collected data of T2D patients who initiated new GLP-1RA between 2010 and 2018. We recorded baseline characteristics, including demographics, anthropometrics, cardiovascular risk factors, glucose control, lipid profile, liver enzymes, renal function and concomitant medications. We recorded updated HbA1c and body weight at follow-up. Results: There were 83,116 T2D patients from a general population of ~ 1,380,000 inhabitants. Among 6167 cases of GLP-1RA initiation, 5408 were analyzed after excluding intra-class switchers. Prescription of GLP-1RA increased exponentially, and the change in the type of GLP-1RA reflected waves of their entering the market. From 2010 to 2018, there were significant increases in baseline age, diabetes duration and prevalence of male sex, of cardiovascular disease and of insulin users. Blood pressure and cholesterol levels decreased concomitantly with increasing use of medications for the control of cardiovascular risk. Baseline average HbA1c (8.3% [67 mmol/mol]) and BMI (34 kg/m
2 ) and their improvement after GLP-1RA initiation did not change over time. Conclusions: Despite the early positioning of GLP-1RA in T2D treatment algorithms, GLP-1RA have been prescribed in patients with progressively more advanced disease stage and especially in the presence of cardiovascular disease. Optimization of GLP-1RA use in routine clinical practice is still needed. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
3. Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.
- Author
-
Morieri, Mario Luca, Rigato, Mauro, Frison, Vera, Simioni, Natalino, D'Ambrosio, Michele, Tadiotto, Federica, Paccagnella, Agostino, Lapolla, Annunziata, Avogaro, Angelo, and Fadini, Gian Paolo
- Subjects
TYPE 2 diabetes ,GLUCAGON-like peptide-1 agonists ,INSULIN aspart ,WEIGHT loss ,SYSTOLIC blood pressure ,INSULIN - Abstract
Background and Aims: The combination of basal insulin (BI) and GLP‐1 receptor agonists (GLP‐1RAs) is a rational and effective therapy for patients with uncontrolled type 2 diabetes (T2D). We compared the effectiveness of fixed and flexible BI/GLP‐1RA combinations using routinely accumulated clinical data. Methods: This was a retrospective, multicentre, real‐world study concerning T2D patients initiating a fixed or flexible BI/GLP‐1RA combination (NCT03959865). The primary endpoint was change in HbA1c. Secondary endpoints were changes in body weight, fasting plasma glucose (FPG) and systolic blood pressure (SBP). Confounding was addressed by propensity score matching (PSM) or multivariable adjustment (MVA). Results: A total of 609 patients were included in the study, 131 in the fixed group and 478 in the flexible group. The two groups differed in terms of diabetes duration, body weight and concomitant medications. After 5.7 months, observed HbA1c reductions were 0.6% and 0.8%, and body weight reductions were 2.8 kg and 1.2 kg in the flexible and fixed groups, respectively. Following PSM, HbA1c declined similarly in the two groups, whereas reduction in body weight was significantly in favour of the flexible combination. Findings were robust in sensitivity analyses, with the exception that, with MVA, a significantly higher reduction in HbA1c was detected in the fixed group. Final doses of BI were higher in the fixed group, whereas those of GLP‐1RA were higher in the flexible group. Conclusions: In routine specialist care, initiation of the fixed or flexible BI/GLP‐1RA combination allowed similar improvement in glycaemic control, but greater weight loss was observed with the flexible combination. This difference reflected dosages of BI and GLP‐1RAs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Correlation Between Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in Italy.
- Author
-
Lapolla, Annunziata, Frison, Vera, Bettio, Michela, Dal Pos, Michela, Rocchini, Paola, Panebianco, Giuseppe, Tadiotto, Federica, Da Tos, Virgilio, D'Ambrosio, Michele, Marangoni, Alberto, Ferrari, Maria, Pianta, Alessandro, Balzano, Sara, Confortin, Loris, Lamonica, Mario, Marin, Narciso, Strazzabosco, Marco, Brun, Elisabetta, Mesturino, Chiara Alberta, and Simoncini, Maria
- Subjects
- *
ACADEMIC medical centers , *ANALYSIS of variance , *BLOOD testing , *CONFIDENCE intervals , *DIABETES , *LIPIDS , *LONGITUDINAL method , *MEDICAL cooperation , *METABOLIC regulation , *MULTIVARIATE analysis , *TYPE 2 diabetes , *REGRESSION analysis , *RESEARCH , *STATISTICS , *T-test (Statistics) , *WEIGHT loss , *LOGISTIC regression analysis , *DATA analysis , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *GLUCAGON-like peptide-1 agonists , *ODDS ratio , *MANN Whitney U Test , *KRUSKAL-Wallis Test , *THERAPEUTICS - Abstract
Purpose: Treatment with liraglutide in randomized controlled trials is associated with significant reductions in glycated hemoglobin (HbA1c) and weight loss in type 2 diabetes patients. The aim of this retrospective observational study was to investigate correlations of glycemic control and weight outcomes with baseline characteristics of patients starting liraglutide in outpatient clinics in Italy. Methods: Type 2 diabetes patients were followed from baseline to 4, 8, and 12 months. Changes in glycemic parameters, weight, blood pressure, and lipids were assessed. Subanalyses were performed according to baseline characteristics. Multivariate linear and logistic regressions were used to assess correlations between glycemic efficacy, weight reduction, and liraglutide discontinuation after 12 months and baseline characteristics. Findings: Four hundred and eighty-one patients were included. Mean (SD) age at baseline was 57.3 (9.2) years, diabetes duration was 9.5 (6.8) years, weight was 106.7 (20.8) kg, body mass index (BMI; calculated as kg/m²) was 37.1 (6.6), HbA1c was 8.7% (1.3%), fasting plasma glucose was 168.5 (45.3) mg/dL; 38.2% were treated previously with insulin and 52.2% were treated with metformin alone. After 12 months, mean (SD) changes were HbA1c 1.2% (1.4%), fasting plasma glucose -28.3 (41.1) mg/dL, weight -3.5 (5.8) kg, BMI -1.3 (2.1), waist circumference -2.6 (6.7) cm (all, P < 0.001). Drop in weight and HbA1c did not differ between baseline BMI classes ≤30 or >30. Weight loss was unchanged among diabetes duration quartiles, and HbA1c reduction was significantly greater in patients with ≤4 years of diabetes duration (P = 0.01). Non-insulin-treated patients reached HbA1c ≤7% significantly more often than treated patients (44.2% vs 21.2%; odds ratio =2.94; P < 0.001) and had significantly greater weight loss (-4.5 [8.2] kg vs -2.6 [5.4] kg; P = 0.03). Patients on metformin reached HbA1c target more frequently than others (43.1% vs 29.7%; odds ratio = 1.80; 95% CI, 1.05-3.07). Significant positive determinants for HbA1c reduction after 12 months were baseline HbA1c, age, and prior metformin monotherapy, and weight loss at 12 months was positively correlated with baseline weight, and negatively correlated with prior insulin treatment. Overall, 5.0% of patients interrupted liraglutide before the 12th month due to lack of glycemic control; they were less frequently treated with metformin only before liraglutide (29.2% vs 50.2%; P = 0.04). Implications: Treatment with liraglutide in a realworld setting is associated with low therapy failure, good glycemic response, weight loss, and improvement in systolic blood pressure and lipid profile. The HbA1c drop did not differ among baseline BMI classes, indicating that efficacy is maintained in patients with lower BMI. The probability of reaching HbA1c ≤7% was significantly higher in patients previously treated with metformin alone and without any previous insulin. This could reinforce the hypothesis that better results with liraglutide could be achieved in patients after early metformin failure. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.
- Author
-
Bonora, Benedetta Maria, Rigato, Mauro, Frison, Vera, D'Ambrosio, Michele, Tadiotto, Federica, Lapolla, Annunziata, Simioni, Natalino, Paccagnella, Agostino, Avogaro, Angelo, and Fadini, Gian Paolo
- Subjects
- *
TYPE 2 diabetes , *BOLUS radiotherapy , *INSULIN , *BLOOD sugar , *GLUCAGON-like peptide-1 agonists , *INSULIN therapy , *RESEARCH , *RESEARCH methodology , *HYPOGLYCEMIC agents , *RETROSPECTIVE studies , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *PHARMACODYNAMICS - Abstract
Aims: We evaluated de-intensification of basal-bolus insulin (BBI) after initiation of a GLP-1 receptor agonist (GLP-1RA) under routine care.Research Design and Methods: This retrospective, multicenter study conducted at outpatient clinics in North-East Italy collected data on patients with T2D on BBI who initiated a GLP-1RA. Patients were divided according to whether they de-intensified BBI at the end of observation by stopping prandial insulin.Results: We included 425 patients with mean age of 61.3 years and 13 years of diabetes duration. Baseline HbA1c was 8.6% and BMI was 35.5 kg/m2. After 14 months. 58.6% of patients de-intensified BBI after initiating GLP-1RA: they were younger, had a shorter disease duration, lower HbA1c and insulin dose, and less frequent microangiopathy than those who continued BBI. A probability estimation based on these variables was validated in an independent cohort of 40 patients. Body weight improved in both groups, but HbA1c and fasting plasma glucose significantly declined only among patients who de-intensified BBI. Patients who de-intensified BBI and persisted on GLP-1RA at the last observation (80.7%) had greater HbA1c reductions.Conclusion: Under routine care, GLP-1RA initiation frequently allowed discontinuing BBI, especially among patients with shorter disease duration, lower insulin requirement, and better glucose control. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.